Skip to main content

Table 3 Observed and/or reported adverse events during the first 7 days after the start of treatment

From: Efficacy of two artemisinin-based combinations for the treatment of malaria in pregnancy in India: a randomized controlled trial

Event

ASSP (n = 125) N (%)

ASMQ (n = 123) N (%)

Total (n = 248) N (%)

p-value

Anaemia (< 11 g/dL)

18 (14.4)

17 (13.8)

35 (14.1)

0.896

Weakness

22 (17.6)

19 (15.4)

41 (16.5)

0.648

Nausea

4 (3.2)

9 (7.3)

13 (5.2)

0.146

Vomiting

2 (1.6)

15 (12.2)

17 (6.9)

0.001

Headache

7 (5.6)

3 (2.4)

10 (4.0)

0.206

Diarrhoea

2 (1.6)

6 (4.9)

8 (3.2)

0.144

Dizziness

11 (8.8)

12 (9.8)

23 (9.3)

0.795

Lower abdominal pain

8 (6.4)

4 (3.3)

12 (4.8)

0.248

Pruritus

2 (1.6)

1 (0.8)

3 (1.2)

0.571

Tinnitus

5 (4.0)

5 (4.1)

10 (4.0)

0.979